Walvax Biotechnology Co., Ltd. Walvax Biotechnology Co., Ltd. (300142.SZ) is a China-based biopharmaceutical company principally engaged in the research, development, production and distribution of human vaccines. The company offers a portfolio of vaccines including 13-valent pneumococcal polysaccharide conjugate vaccine for infants and children; 23-valent pneumococcal polysaccharide vaccine; group A and C meningococcal polysaccharide conjugate vaccine; group A and C meningococcal polysaccharide vaccine; ACYW135 group meningococcal polysaccharide vaccine; haemophilus influenzae type b conjugate vaccine for children; diphtheria, tetanus and acellular pertussis combined vaccine (DTaP) for infants and children; recombinant bivalent human papillomavirus vaccine (types 16/18, HPV-2, or Pichy yeast); SARS-CoV-2 mRNA vaccines such as ARCoV and Omicron XBB.1.5 variant; and recombinant subunit COVID-19 vaccines. Founded in 2001 and headquartered in Kunming, Yunnan Province, China, Walvax operates primarily in the domestic market with exports to countries including Indonesia, Morocco, Egypt, and the Philippines, and maintains advanced R&D platforms for polysaccharide, conjugate, recombinant protein, VLP and mRNA vaccines.
In recent developments, Walvax's recombinant bivalent HPV vaccine (HPV-2) received World Health Organization prequalification in August 2024 and launched commercially in China in 2022; its SARS-CoV-2 mRNA vaccine (Omicron XBB.1.5) obtained Emergency Use Authorization from China's NMPA; and its 13-valent pneumococcal conjugate vaccine was exported to Morocco for inclusion in the national immunization program. The company expanded collaborations with CEPI and Shanghai Zerun Biotechnology for COVID-19 multi-variant vaccines, including Phase I/II trials in Mali supported by up to USD 8.15 million in funding. In July 2025, Walvax signed a three-year global strategy cooperation framework agreement with Yuxi State-owned Capital Operation Co., Ltd. to support industrial upgrades, equity optimization and mergers in innovative vaccines and biologics; and in November 2025, entered a two-year memorandum of understanding with Mirxes Holding Company Limited for an RNA-centric preventive medicine platform encompassing joint development, trials and commercialization leveraging mRNA technologies and ASEAN distribution. Walvax continues partnerships with global organizations such as WHO, UNICEF, PATH, GAVI, CEPI, DCVMN and the Bill & Melinda Gates Foundation to advance affordable vaccines for emerging diseases.